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Abstract 
A clinical association between idiopathic liver disease and parvovirus B19 infection has been 
observed. Fulminant liver failure, not associated with other liver-tropic viruses, has been at-
tributed to B19 in numerous reports, suggesting a possible role for B19 components in the 
extensive hepatocyte cytotoxicity observed in this condition. A recent report by Abe and 
colleagues (Int J Med Sci. 2007;4:105-9) demonstrated a link between persistent parvovirus 
B19 genotype I and III infection and fulminant liver failure. The genetic analysis of isolates 
obtained from these patients demonstrated a conservation of key amino acids in the non-
structural protein 1 (NS1) of the disease-associated genotypes. In this report we examine a 
conserved residue identified by Abe and colleagues and show that substitution of isoleucine 
181 for methionine, as occurs in B19 genotype II, results in the reduction of B19 NS1-induced 
cytotoxicity of liver cells. Our results support the hypothesis that in the setting of persistent 
B19 infection, direct B19 NS1-induced cytotoxicity may play a role in idiopathic fulminant liver 
failure. 
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INTRODUCTION 
Human parvovirus B19 is a ubiquitous infectious 
agent known to cause erythema infectiosum in child-
ren, bone marrow suppression and chronic anemia in 
susceptible individuals, and fetal hydrops and death 
in intrauterine infections (2, 25). Studies have also 
linked the virus to numerous idiopathic conditions 
such as systemic lupus erythematosus (SLE)-like 
syndromes, rheumatoid-like arthritis, and liver and 
kidney disease (10, 27, 37, 40). The role of B19 in the 
latter set of pathologies is difficult to discern because 
the cellular tropism of the virus for erythroid precur-
sor cells (33) excludes viral replication as being the 
cause of the observed cellular damage in replication 
nonpermissive tissues. Two major hypotheses have 
been proposed to explain the potential role of B19 in 
such phenomena: an immune mediated attack of 
end-organ antigens due to B19-induced molecular 
mimicry (22, 43), or direct B19-mediated cellular 
damage in the absence of viral particle replication 
(43). Evidence for both mechanisms exists and it is 
possible that both have a role to play in the diverse 
clinical picture of B19 disease.  
The B19 linear, single-stranded DNA genome 
encodes three major viral proteins; two structural 
capsid proteins (VP1 and VP2) and three 
non-structural proteins (the major 77 kDa NS1 and the Int. J. Med. Sci. 2010, 7 
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minor 11 kDa and 7.5 kDa proteins, the latter two 
whose functions remain unclear) (39, 48). The hu-
moral response to B19 infection is initially directed 
against the major viral capsid protein VP2. As the 
recovery process progresses, however, this response 
becomes replaced by antibodies against the unique 
region of VP1 (24). It has been suggested that im-
mune-mediated tissue injury in B19 infection may be 
the result of cross-reactivity between IgG antibodies 
against VP epitopes and human antigens (22, 23). On 
the other hand, the non-structural protein of B19 
(NS1) is a candidate mediator of direct cell injury.  
B19 virus targets erythroid cells via the major 
host cell receptor glycolipid globoside, also known as 
the blood group P antigen (4), as well as two core-
ceptors, α5β1 and Ku80. The presence of P antigen, 
however, is not sufficient for B19 replication (43). 
Studies have suggested that intracellular conditions, 
such as viral DNA transcription and RNA processing, 
are involved in establishing cell permissiveness (5, 14, 
21). However, tissues identified as non-permissive for 
B19 replication have been shown to harbor genomic 
evidence of B19 infection for extended periods of time 
(7, 40). Although such non-permissive cells display an 
inability to produce viral structural proteins and rep-
licate the viral genome, curiously these same tissues 
allow transcription and translation of NS1 (18, 34, 47).  
The non-structural NS proteins of parvoviruses 
are central to the viral life cycle, mediating viral ge-
nome transcription, replication, and packaging. These 
multi-domain proteins have a conserved architecture: 
the N-terminus encodes for the DNA binding and 
endonuclease domains (30, 45); the central region 
contains the conserved NTP-binding and helicase 
motifs that identify the protein as a member of the 
AAA+ SF3 helicase group (9, 13, 25); and the unique 
C-terminus region has been suggested to be involved 
in host-protein interactions and promoter 
trans-activation activity (10, 19, 31). The three major 
genotypes of B19 have been shown to have most of 
their nucleotide diversity localized to the C-terminus 
region of its non-structural protein (16, 37). However, 
until recently no specific amino acid variation has 
been associated with a single clinical presentation of 
B19 disease (16, 20). In 2007, Abe and colleagues (1) 
performed a sequence analysis of B19 NS1 isolated 
from the livers of two patient groups; group A con-
tained patients with idiopathic fulminant hepatitis 
while group B was made up of patients with biliary 
atresia. The study correlated the presence of geno-
types 1 and 3 in patients with idiopathic fulminant 
hepatitis, while only genotype 2 was identified in pa-
tients with biliary atresia. Furthermore, conserved 
(I181M, E201D) amino acid substitutions were identi-
fied in patients with biliary atresia that were not ob-
served in the fulminant hepatitis group. Since biliary 
atresia is a congential condition yet to be linked with 
an infectious cause (36), identification of conserved 
amino acid substitutions in the B19 NS1 isolates of 
only the group A patients suggests that these residues 
may be critical to the mechanism of B19-associated 
fulminant liver failure.  
B19 has long been linked with a spectrum of liver 
disease ranging from self-limited hepatitis to acute 
fulminant liver failure (18, 28, 46). The significant as-
sociation of bone marrow suppression with acute 
fulminant liver failure in the pediatric population (6, 
15) along with the isolation of B19 DNA from liver 
tissue (12), which has been shown to be 
non-permissive for viral replication (3), but allows 
transcription and translation of B19 NS1 (18, 34), has 
lead us to examine the potential role of B19 NS1 in 
direct hepatocyte cytotoxicity. Our laboratory pre-
viously demonstrated that B19 NS1 caused apoptosis 
in liver-derived cells (34, 35). The above described 
study by Abe et al. (1) led us to explore the effect of 
the NS1 I181M amino acid substitution on B19 
NS1-induced cytotoxicity in liver cells. Our work has 
shown that the I181M substitution significantly re-
duces B19 NS1-induced apoptosis in HepG2 cells, 
suggesting an important role for this residue in the 
mechanism of B19 NS1-induced liver cytotoxicity.  
MATERIALS AND METHODS  
Cell Culture. Spodoptera frugiperda-derived SF9 
cells were cultured in spinner flasks using BioWhit-
taker® Insect-XPress cell media (BioWhittaker® , 
Walkersville, MD) supplemented with 1% Penicil-
lin-Streptomycin (PenStrep) (Gibco®, Invitrogen, 
Carlsbad, CA) at 27°C. HepG2 cells were cultured in 
Hepatocyte Wash Media (Gibco®) supplemented 
with 10% Fetal Bovine Serum (FBS) (Gibco®), 1% 
L-glutamine (Gibco®) and 1% PenStrep. The cells 
were incubated at 37°C in 5% CO2.  
Cloning and Recombinant Baculovirus Pro-
duction. A modified pFastBac1 (Invitrogen, Carlsbad, 
CA) vector was used as a backbone for the generation 
of B19 NS1 expressing baculovirus. The polyhedrin 
promoter was removed from the pFastBac1 plasmid 
by SnaB1 (Fermentas, Glen Burnie, MD) and BamH1 
(Fermentas) digestion. The Cytomegalovirus (CMV) 
immediate-early promoter was obtained from 
pcDNA3.1 (Invitrogen) by NruI (Fermentas) and 
BamH1 digestion and used to replace the 
SnaB1-BamH1 fragment in pFastBac1, resulting in 
pCMVFastBac1. The vector was again digested with 
Nhe1 (Fermentas) and BamH1 in order to insert a 
fragment encoding the Enhanced GFP (EGFP) protein Int. J. Med. Sci. 2010, 7 
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obtained from pEGFP-C1 (Clontech Laboratories Inc., 
Saint-Germain-en-Laye, France) using the same re-
striction enzymes, resulting in pCMVEGFPwoFast-
Bac1. The native B19 NS1 sequence was obtained from 
the PBDP2 vector (34). Mutagenesis of the native se-
quence was performed using the sequential PCR 
technique (8). Briefly, two overlapping fragments of 
the desired mutant construct were produced using 
unique internal oligonucleotides encoding a collection 
of point mutations and deletions and B19 NS1 generic 
external primers (Table 1). The two fragments were 
then annealed by mutually primed synthesis using 
the EcoR1 (Fermentas) and Xba1 (Fermentas) encod-
ing B19 NS1 generic external primers (Table 1). The 
following mutants were generated: PathT, a single 
amino acid replacement, T183A, and PathI, a single 
amino acid replacement, I181M. The NS1 constructs 
were ligated into the EcoR1-Xba1 digested 
pCMVEGFPwoFastBac1 vector backbone to produce 
the desired EGFP-NS1 fusion protein and its muta-
tions under the CMV immediate-early promoter.  
Recombinant baculoviruses were prepared using 
the Bac-to-Bac® Baculovirus Expression system (In-
vitrogen). Third generation virus was collected by 
centrifugation at 1500 x g for 10 min. Sterile inacti-
vated fetal bovine serum (FBS) (Gibco®) was added to 
each virus to make a 10% solution after which the 
stock was filtered through a 0.2 µm filter (Millipore, 
Billerica, MA) and stored at 4°C.  
Table 1. Primers Used for B19 NS1 and Substitution 
Construct Cloning.  
 Construct   Primer 
  
 External 
Primers 
 
  
 F- 5’ GGCGACGAATTCATGGAGCTATTTAG GG  
 R- 5’ 
GGCCATCTAGATTACTCATAATCTACAAAGCT 
  
 PathT - 
PRMTTA 
 
  
 1- 5’ AGTATCATTTATGGCTACGGTAATG  
 2- 5’ ATTACCGTAGCCATAAATGATACTAGTAG  
 
Baculovirus Transduction of HepG2 Cells. 
HepG2 cells were seeded in culture flasks and grown 
overnight in supplemented media as described above. 
The following day the media was removed, cells 
washed once with sterile phosphate buffered saline 
(PBS), and the baculovirus solution added to the cul-
ture flask. A multiplicity of infection (moi) equivalent 
to ~100-200 was used for each experiment, resulting in 
a transduction efficiency of ~25% for each virus at 24 
hrs post-transduction. The treated HepG2 cells were 
kept on ice and remained immersed in the baculovi-
rus solution for 1 hr to promote viral binding to the 
cellular membrane, after which the virus suspension 
was removed, the cells washed once with sterile PBS 
and then pre-warmed supplemented media added. 
Transduced HepG2 cells were stored at 37°C in 5% 
CO2. Transduction efficiency was established using 
flow cytometry as described below.  
Flow Cytometry. HepG2 cells were collected by 
trypsinization (0.5% Trypsin EDTA (Gibco®) in PBS 
(Gibco®) at indicated times, washed once with fresh 
media (500 µL) and counted to prepare required cell 
numbers per sample for each experiment. For trans-
duction efficiency analysis, 5 x 10
5 
HepG2 cells were 
resuspended in 500 µL of ice-cold PBS and imme-
diately analyzed by flow cytometry. For AnnexinV 
binding analysis 5 x 10
5 
cells were washed once with 
PBS and resuspended in 500 µL AnnexinV Binding 
Buffer and 5 µL AnnexinV-PE (AMS Biotechnology 
LTD., Abington, OX, UK), incubated for 15 min at 
room temperature in the dark and immediately ana-
lyzed by flow cytometry. The percentage of cells ex-
pressing the EGFP marker, as well as the distribution 
of signal intensity for each construct transduced, were 
established, in order to ensure that a comparable 
amount of protein was being expressed in each con-
struct transduction, for the comparison of different 
NS1 mutant groups.  
  For examination of apoptosis using the SubG1 
population in cell cycle analysis, 3 x 106 cells were 
washed once with ice cold PBS and fixed in 70% 
ice-cold ethanol (900 μl) for 24-48 hrs at 4°C. The fixed 
cells were washed twice with PBS to rehydrate the 
sample and incubated in propidium iodide 40 μg/ml 
(Molecular Probes (Invitrogen), Carlsbad, CA) and 
RNase 40 μg/ml (Roche Basel, Switzerland) in PBS at 
37°C for 20 min. The cells were centrifuged, resus-
pended in ice-cold PBS and immediately analyzed by 
flow cytometry.  
  All samples were analyzed on the 
FACSCALIBUR flow cytometer (Becton-Dickson, 
Frankline Lakes, NJ), data collected using Cell-Quest 
software (Becton-Dickson), and statistical analysis 
completed by FlowJo software (Tree Star, Inc, Ash-
land, OR).  
Cytotoxicity Assay. Trypan blue dye exclusion 
was used to determine cell viability. Adherent and 
loose HepG2 cells were collected by trypsinization 
(0.5% Trypsin EDTA (Gibco®) in PBS (Gibco®) at 
indicated times and washed once in sterile PBS. The 
cells were then resuspended 1:10 in trypan blue solu-
tion (0.8 mM trypan blue in PBS) and incub ated at  
room temperature 2-5 min. The cells were counted 
using a hemocytometer and trypan blue stained cells 
were identified. The results were quantified as num-
ber of trypan blue staining cells out of total cells 
counted.  Int. J. Med. Sci. 2010, 7 
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Statistical Analysis. Student t-test was used to 
assess the statistical significance in the data.  
RESULTS  
Substitution I181M in B19 NS1 interferes with 
NS1-induced apoptotic cell death. To test the hypo-
thesis that B19-associated liver pathology is related to 
the direct toxicity of persistent B19 NS1 in hepatocytes 
of previously infected individuals, we examined the 
possible role of specific amino acid variation in the 
B19 NS1 protein on liver toxicity. The clinical obser-
vation by Abe et al. (1) of B19 genotype variability in 
different liver disease groups, identified two amino 
acid substitutions in B19 NS1 that differed between 
the biliary atresia and fulminant liver failure patient 
groups. Substitution E201D, believed to be in the B 
cell epitope of B19 NS1 (40), substituted one acidic 
residue for another, suggesting a conserved mutation 
that would not significantly change the chemical 
properties of the protein. An immunological analysis 
o f  B - c e l l  a c t i v a t i o n  w o u l d  n e e d  t o  b e  c o m p l e t e d  i n  
order to understand the potential impact of this subs-
titution on B19 NS1. Therefore, we focused our anal-
ysis on the second substitution, I181M, observed only 
in genotype 2-carrying biliary atresia patients. We 
created EGFP tagged constructs of wild type genotype 
1, I181M (PathI) substitution and T183A (PathT) 
substitution of B19 NS1 under the CMV immediate 
early promoter. The PathT substitution was observed 
in genotype 3 of B19 but not in genotype 1, both of 
which could be found in patients with fulminant liver 
failure, and was used as a second negative control, 
along with the wild-type B19 NS1 construct. These 
constructs were cloned into the baculovirus expres-
sion system, which was used as a gene delivery ve-
hicle.  
24 hrs post-transduction of HepG2 cells with 
baculovirus carrying the above described B19 NS1 
constructs, trypan blue dye uptake analysis showed 
an increased amount of cell death in cells expressing 
B19 NS1-derived proteins compared to mock infected 
(Cell) or EGFP expressing cells (Figure 1). Although 
slightly less death could be seen in the PathI trans-
duced cells at 24 hr post-transduction, the difference 
between the constructs was not statistically signifi-
cant. HepG2 cell cytotoxicity continued to increase as 
the cells continued to express B19 NS1. At 48 hrs 
post-transduction 36% (Figure 1) of HepG2 cells ex-
pressing wild-type NS1 showed loss of viability. 
HepG2 cells transduced with constructs expressing 
PathI and PathT exhibited a similar pattern of cell 
loss, with continued decline in cell viability until 48 
hrs post-transduction. However, unlike wild-type B19 
NS1- and PathT-transduced cells, approximately 10% 
fewer PathI mutant transduced HepG2 cells showed 
trypan blue uptake at 48 hrs post-transduction (p = 
0.0002) (Figure 1).  
Previous studies have identified apoptosis as the 
underlying mechanism for the cytotoxicity observed 
in the setting of transient B19 NS1 expression (34). We 
therefore examined whether the reduced cell loss ob-
served in the PathI substitution- carrying HepG2 cells 
resulted from a reduction in cells undergoing apop-
tosis. We used the AnnexinV binding assay to assess 
apoptotic cell death in HepG2 cells. The pattern of 
apoptosis observed in HepG2 cells expressing all B19 
NS1 constructs showed continually increasing per-
centage of cells undergoing apoptosis starting at 24 
hrs (Figure 2). At 48 hrs post-transduction the PathI 
construct expressing cells displayed approximately 
18% less apoptotic cell death than the wild-type and 
PathT B19 NS1-expressing cells (p = 0.023) (Figure 2). 
The reduced apoptotic cell death in the Pa-
thI-expressing cells resembled the reduction observed 
with the generalized cytotoxicity assay, suggesting 
that the reduced cell loss is due to a decrease in B19 
NS1-induced cell suicide, previously reported to be 
the mechanism of B19 NS1-induced cytotoxicity (34, 
35).    
Further confirmation for the reduction of apop-
tosis in the PathI transduced population of HepG2 
cells was obtained using cell cycle analysis of HepG2 
cells expressing the wild-type and mutant B19 con-
structs. Non-transduced HepG2 cells, HepG2 cells 
transduced with moi 400 of non-engineered baculo-
virus, and HepG2 cells transduced with EGFP ex-
pressing virus to 95% transduction efficiency at 24 hrs 
post-transduction were used to establish HepG2 cell 
cycle distribution (negative controls). G0/G1, S, 
G2/M and SubG1 (representing cells undergoing 
apoptotic cell death) phases were identified on the 
linear fluorescence intensity plots for propidium 
iodide emission (Figure 3A). All three negative con-
trol conditions displayed the same pattern of cell cycle 
progression with approximate distribution of cells at 
48 hrs as follows; 71% G1, 16% S, 12% G2 and 1% 
SubG1 (data not shown). For clarity only one repre-
sentative negative control condition, labeled Cell, is 
presented in Figure 3. 
  HepG2 cells transduced with baculovirus car-
rying the NS1 constructs were identified by flow cy-
tometry and subsequent cell cycle analysis performed. 
The pattern of cell cycle distribution for NS1 ex-
pressing cells differed significantly from that seen for 
the negative controls (Figure 3A bottom panels). At 48 
hrs post-transduction 20% of HepG2 cells expressing 
the NS1 construct were in the SubG1 population 
(Figure 3B). The SubG1 accumulation demonstrated Int. J. Med. Sci. 2010, 7 
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the cytotoxic nature of B19 NS1, which has been pre-
viously shown to cause apoptotic cell death in HepG2 
cells.  
The cell cycle observations for NS1 expressing 
cells were then compared to cells expressing the PathT 
and PathI mutation constructs. At 24 hrs 
post-transduction all mutant NS1 proteins exhibited a 
similar effect on HepG2 cells as the wild-type NS1 
protein with approximately 3% of cells in the SubG1 
population (Figure 3B). At 48 hrs post-transduction, 
however, a mean of 24.5 % of HepG2 cells expressing 
the PathT construct were found in the SubG1 popula-
tion (Figure 3B). In contrast to this, only 11.5% of PathI 
expressing HepG2 cells were identified in the SubG1 
population (Figure 3B), suggesting a significant re-
duction in apoptotic cell death (p = 0.0317) compared 
to the PathT construct expressing HepG2 cells. No 
statistical significance was identified between the 
wild-type NS1 and PathT construct expressing cells, 
which we believe is due to the large variability in the 
SubG1 content data for the wild-type NS1 transduc-
tion. 
 
 
Figure 1. Cytotoxicity Assay. HepG2 cells were mock, EGFP-, NS1-, PathT-, or PathI- transduced, collected at indicated 
times post-transduction and analyzed by trypan blue exclusion. The data represent the mean of three independent expe-
riments demonstrating the percentage of total cells in the sample permeable to trypan blue uptake. One star (*) – statistically 
significant (p < 0.05) change between Cell and marked set. Two stars (**) – statistically significant (p< 0.05) change between 
NS1 and marked set. Bars demonstrate the standard deviation between individual runs. 
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Figure 2. AnnexinV Binding Assay. HepG2 cells were mock, EGFP-, NS1-, PathT-, or PathI-transduced, collected at 
indicated times post-transduction, and analyzed by flow cytometry for AnnexinV binding. Graphic representation of the 
means of three independent experiments, demonstrating the percentage of EGFP or EGFP-fusion protein expressing HepG2 
cells that bind AnnexinV-PE, as identified by flow cytometry analysis. The AnnexinV results have been normalized for 
background AnnexinV-PE binding using mock-transduced cells. Bars demonstrate the standard deviation between individual 
runs. One star (*) – statistically significant (p < 0.05) change between Cell and marked set. Two stars (**) – statistically 
significant (p< 0.05) change between NS1 and marked set.  Int. J. Med. Sci. 2010, 7 
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Figure 3. Cell Cycle Analysis for SubG1 Content. (A) Representative fluorescence intensity plots for propidium 
iodide emission demonstrating the cell cycle distribution of mock-transduced control (top) and NS1 (bottom) expressing 
HepG2 cells at 24 and 48 hrs post-transduction. (B) Quantitative graphic representation of HepG2 cell cycle distribution for 
mock, NS1, PathT and PathI in the SubG1 phase of the cell cycle. The data represents at least two independent experiments 
with bars demonstrating the standard deviation between the individual runs. One star (*) indicates statistically significant (p 
< 0.05) change between Cell and marked set. Two stars (**) – statistically significant (p< 0.05) change between NS1 and 
marked set. Three stars (***) – statistically significant (p< 0.05) change between PathT and marked set. 
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DISCUSSION  
Suggestions of a clinical link between B19 and a 
variety of liver disorders have been reported in the 
literature (18, 29, 46). However, the mechanism for 
B19- induced hepatotoxicity remains obscure. Two 
hypotheses have been proposed: immune-mediated 
hepatocyte damage resulting from B19-induced mo-
lecular mimicry (23, 46), or direct liver toxicity from 
B19 infection of hepatocytes (34, 46). We have pre-
viously shown that B19 can infect liver cells and 
transcribe and translate its non-structural protein (35). 
Expression of NS1 in primary hepatocytes as well as 
in HepG2 cells was shown to be cytotoxic (34). Acti-
vation of the innate apoptotic cascade was demon-
strated to be the route of cell demise in the setting of 
B19 NS1 over-expression, suggesting direct 
NS1-induced cellular damage (35). The endogenous 
apoptotic cascade is often activated in cells that can-
not overcome a set of well defined cellular insults 
such as an accumulation of DNA damage, disruptions 
in mitochondrial membrane integrity, or interference 
with the dynamic cytoskeletal network. Studies with 
B19 and other parvoviruses have suggested that the 
parvoviral non-structural protein can potentially in-
terfere with cellular cytoskeleton proteins (31), induce 
DNA damage (32), and promote mitochondrial 
apoptotic activation (17). This evidence along with 
our own observations led us to investigate the role of 
direct B19 injury to hepatocytes in the setting of B19- 
associated liver disease.  
Parvoviral non-structural proteins are essential 
for viral replication and packaging, serving numerous 
roles in the viral life cycle. The multi-domain archi-
tecture of parvoviral non-structural proteins results in 
high conservation of their sequence identity, espe-
cially within the well-characterized catalytic regions, 
such as the endonuclease and NTP-binding motifs. 
The highly integrated functions of complex proteins 
can often be interrupted by single, well placed, amino 
acid disruptions, which can potentially change the 
native folding, catalytic capacity, oligomerization 
state, or other inter-protein interactions. The identifi-
cation by Abe and colleagues (1) of an amino acid 
substitution in the NS1 protein of B19 genotype 2 that 
could not be observed in NS1 proteins isolated from 
livers of patients with fulminant liver failure, 
prompted us to explore whether this amino acid 
substitution can effect B19 NS1’s cytotoxicity in liver 
derived cells. In this study, we have demonstrated 
that substitution I181M significantly reduces geno-
type 1 B19 NS1’s cytotoxicity in HepG2 cells. Fur-
thermore, apoptosis was reduced by the PathI con-
struct of B19 NS1, suggesting that the disruption is in 
the mechanism by which B19 NS1 induces apoptosis 
in liver cells.  
Due to a lack of structural information about B19 
NS1, the role of residue 181 in NS1 function is unclear. 
The residue does not appear to fall into the clearly 
identifiable conserved motifs, such as the endonuc-
lease metal coordination motif HuHuu (residues 
81-85), or NTP binding p-loop, GXXXXGK (residues 
328-334), seen in all parvoviral non-structural pro-
teins. However, even though the primary structure is 
not telling, the contribution of this residue to the 
overall structure of the enzymatic folds can be pro-
posed. The change from a hydrophobic residue to a 
more polar one also suggests a disruption in the po-
tential orientation of the side chain and hence a 
change in the secondary structure of that region in the 
protein. Since the I181M substitution did not oblite-
rate B19 NS1 cytotoxicity, but only reduced it, the 
protein continues to maintain some function, sug-
gesting that this substitution may also reduce viral 
fitness. B19 replication is difficult to study due to the 
lack of an efficient B19 viral replicon and therefore 
direct experimental verification of the role of amino 
acid variation on replication efficiency or viral fitness 
must await the availability of such tools. However, 
based on the results of this study, we can conclude 
that substitution I181M reduces B19 NS1 cytotoxicity 
in liver cells, potentially resulting in reduced hepato-
cyte dropout and thereby a reduced burden of 
B19-related liver disease.  
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